Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Mar 7, 2023, after the close
10-K filed Mar 7, 2023, 66 days after period end · 0001558370-23-003035
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $51.28M | $20.41M | $18.45M | $15.40M |
| Net Income | $1.40M | -$22.64M | -$19.24M |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$17.20M |
| EPS Diluted | — | — | -$0.11 | -$0.10 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
